WellDoc, whose BlueStar technology is focused on adults with Type 2 diabetes, has drawn $22 million in a Series B round of funding from Samsung Ventures and existing investor Merck Global Health Innovation Fund. The company will use the money to continue commercialization and accelerate adoption of BlueStar.

Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners also participated in the funding round.

Patient Engagement

read more

Source: Healthcare IT News
Click Here: WellDoc scores million for BlueStar diabetes management platform